Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Eur J Haematol ; 62(1): 27-31, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9918308

ABSTRACT

The effect of interferon alpha (IFN) on myeloproliferation and vascular complications was studied in 32 patients (17 female, 15 male; median age 60.5 yr) with polycythemia vera (PV). IFN therapy was initiated at a median time of 19 months after diagnosis. Ten patients were pretreated with chemotherapy in addition to phlebotomy. IFN dose was 12 megaU/wk during the first year, 9 megaU/wk during the second year and 12 megaU/wk thereafter. During IFN alpha treatment hematocrit level was 45.7% and remained at this level after the second year of treatment, compared to 46.5% before IFN. The frequency of phlebotomy before IFN was 0.49/month and dropped to 0.19/month (p <0.0005) during the first year of IFN treatment. IFN normalized high platelet and leukocyte counts in a majority of patients. The incidence of deep venous thromboses was 3.6%/yr before IFN alpha and 1.8%/yr during the first year of treatment. IFN-induced side-effects were mainly flu-like symptoms, fever, fatigue and arthralgia. In conclusion, IFN allowed the reduction of the dose of chemotherapy and decreased the need of phlebotomy. Despite improvement of hematological parameters, it is still uncertain whether IFN alpha can improve clinical symptoms in PV.


Subject(s)
Erythropoiesis/drug effects , Interferon-alpha/pharmacology , Interferon-alpha/therapeutic use , Leukopoiesis/drug effects , Polycythemia Vera/complications , Polycythemia Vera/drug therapy , Thrombosis/drug therapy , Adult , Aged , Aged, 80 and over , Busulfan/therapeutic use , Drug Tolerance , Erysipelas/etiology , Female , Hematocrit , Humans , Hydroxyurea/therapeutic use , Interferon-alpha/adverse effects , Male , Middle Aged , Phlebotomy , Pipobroman/therapeutic use , Polycythemia Vera/pathology , Syncope/etiology , Thrombosis/complications , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...